• Originator Merck Sharp & Dohme
• Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
• Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants; TIGIT protein inhibitors

• Orphan Drug Status

  Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  No
• New Molecular Entity Yes

Highest Development Phases

• Discontinued Biliary cancer; Bladder cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Gastric cancer; Haematological malignancies; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer; Triple negative breast cancer

Most Recent Events

• 17 Sep 2026 Merck Sharp & Dohme terminates the phase-III MK-7684A-003, KEYVIBE-003 trial in Non-small cell lung cancer (Combination therapy, First-line therapy, Metastatic disease, Monotherapy) in Vietnam, USA, Turkey, Ukraine, Thailand, South Africa, Russia, Romania, Philippines, Peru, Mexico, Malaysia, South Korea, Japan, India, Hong Kong, Guatemala, Dominican Republic, China, Chile, Canada, Brazil (IV, Infusion), due to business reasons (NCT04738487)
• 11 Sep 2026 Merck Sharp & Dohme terminates the phase III MK-7684A-007 trial in Non-small cell lung cancer (Metastatic disease, Combination therapy, First-line therapy, In adults, In the elderly, Late-stage disease) due to futility in Argentina, Austria, Brazil, Chile, China, Colombia, France, Germany, Israel, Japan, South Korea, Mexico, Poland, Spain, Taiwan, Thailand, Turkey, UK and the USA (IV) (NCT05226598)
• 02 Jun 2026 Adverse events and efficacy data from a phase I/II ​KEYNOTE-365 trial in Prostate cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO)